General guidance for physicians on the use of the Mental Health Act when treating adults with substance use disorders
March 12, 2025 Dr. Vigo discusses changes to provincial guidelines regarding the use of involuntary care for people with mental health and substance disorders. Image and video source: Global News General guidance for physicians on the use of the Mental Health Act when treating adults with substance use disorders Read More
Excess mortality in COVID-19-negative people with non-communicable disorders during the first pandemic wave
BMC Public Health. 2025 Feb 22;25(1):736. doi: 10.1186/s12889-025-21782-9. Read More
Effective Treatment for Mental and Substance Use Disorders in 21 Countries
New findings from the WHO-Mental Health Surveys Initiative reveal that only 6.9% of individuals with mental health and substance use disorders receive effective treatment for their disorders. This cross-sectional study analyzed data from nearly 57,000 participants across 21 countries, highlighting the steps people with mental health and substance use disorders take in seeking care and […] Read More
Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial
Read about the results of our randomized control trial of Minder! This publication describes the evaluation of Minder‘s effectiveness in improving mental health, substance use, and mental-wellbeing outcomes. Vereschagin, M., Wang, A. Y., Richardson, C. G., Xie, H., Munthali, R. J., Hudec, K. L., Leung, C., Wojcik, K. D., Munro, L., Halli, P., Kessler, R. […] Read More
Suicidal ideation amongst university students during the COVID-19 pandemic: Time trends and risk factors
Dr. Daniel Vigo and his coauthors analyzed 14 months of UBC student data to identify time trends in suicidal ideation over the first three waves of the COVID-19 pandemic in Canada. 18.9% of students experienced suicidal ideation in the previous 30 days of survey response, and suicidal ideation was relatively stable over the course of […] Read More
Determinants of effective treatment coverage for posttraumatic stress disorder: Findings from the World Mental Health Surveys
In this publication, Dr. Daniel Vigo and other WHO World Mental Health Survey Collaborators analyze data from over 35,000 respondents of the WHO World Mental Health Survey to identify determinants of effective treatment coverage for posttraumatic stress disorder (PTSD). Results suggest that a majority of individuals reporting 12-month PTSD did not have adequate pharmacotherapy, psychotherapy, […] Read More
The True Global Disease Burden of Mental Illness: Still Elusive
This new Lancet Psychiatry article critiques the recent Global Burden of Diseases, Injuries, and Risk Factors Study, and re-estimates the burden of mental, neurological, substance use disorders and suicide. Vigo, Jones, Atun & Thornicroft posit that the GBD study did not capture the disability caused by somatoform and personality disorders, and did not include mortality […] Read More
Burden of Mental, Neurological, Substance Use Disorders and Self-Harm in North America
The Canadian Journal of Psychiatry. 2020 Feb;65(2):87-98. Read More
Disease Burden and Government Spending on Mental, Neurological, and Substance Use Disorders, and Self-harm
The Lancet Public Health. Published online November 13, 2018 Read More
Estimating the True Global Burden of Mental Illness
The Lancet Psychiatry. Published February 01, 2016 Read More
Dr. Daniel Vigo
Associate Professor | Department of Psychiatry
DrPH, Harvard University (’17); MD, University of Buenos Aires (’07); Lic. in Psychology (Bachelor’s + Master’s), University of Buenos Aires (’00)